Alnylam Pharmaceuticals, Inc. (ALNY): Investors Should Ignore the Haters And Buy

As volatility creeps into Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), investors need to pay close attention to to the factors affecting stock today as its shares are trading 2.64% or 2.23 points up from last closing price of $84.6, reaching $86.83 at last check. The ALNY share price has risen in 3 of the last 5 days and is up 15.2% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -239,216 shares, and in total 415384 shares valued at $36.068 million were seen changing hands compared with 654600 shares valued at $55.379 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in ALNY stock for the next couple of days.

Alnylam Pharmaceuticals, Inc. (ALNY) shares have notched a 3-month gain of about 15.2%, but has still advanced 16.03% year to date. By comparison, the stock sank -9.76% over the past 12 months, while it jumped 2.99% over the 1 month. The company’s market cap is around $9.35B, with its short interest ratio standing at 8.32%.

In the current trading session for ALNY, the stock witnessed two major price actions, it rose to a high of $87.19 and was down as much as $84.89 at one point. The high recorded is very low when compared to their 52-week high which is $60.27. The 52-week high is now at -9.44 distance from current price. Their recent low of $96.14 represents a 44.46% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for ALNY is $113.39, this is above the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The stock of Alnylam Pharmaceuticals, Inc. earned $-8.27 per share in the trailing 12 months and has a P/E ratio of -10.5. You can compare it with that of similar companies in its industry to get a sense of whether the stock you’re looking to purchase is overvalued or undervalued. Its current price to earnings ratio is lower than the ones recorded by the industry which is 19.36 and lower compared to the sector’s average of 30.72. When the P/E ratio is low let’s say below 1.0, then the stock price is considered a good value. ALNY also has P/S multiple of 94.92. This is greater versus the 12 month P/S ratios of other companies in the same indutry. The peer average price to sales ratio is 2.71x.

ALNY‘s last price was up 10.15% as compared to the average trading price of 50 days recorded at $78.83 while enlarging the period to 200 trading days, the average closing price was $79.29. At present, there are 110.52 million in the total number of common shares owned by the public and among those 110.28 million shares have been available to trade. The percentage of shares being held by the company management was 0.5% while institutions stake was 97%. The company has generated negative returns on equity over the last 12 months (-56.4%). It managed to keep its gross profit margin at 90.6% over the past 12 months.

When assessing the full upside of the ALNY stock, there is another set of technicals that should be looked into and considered. Its 4.67% gain from moving average of $82.96 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 2.38 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Alnylam Pharmaceuticals, Inc. — 11 analysts rate the stock as a buy with another 0 rating it strong buy. There are 4 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $116.1333 on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), which corresponds to 33.53% upside potential than its current market price of $86.83 and implies potential despite the recent advance in the price. However, their current target price has fallen from $121.125 a month ago and is down handily from the consensus target of $127.4444 a quarter ago.

In the last five years, the EPS of the company has been roughly -39.2%. Though the percentage looks disappointing, extra tailwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will increase annually by 46.09%. The revenue of the company has risen at an average annualized rate of about 9.7 over the last five years. The company recently recorded an increase of 49.5%, but this figure is rather attractive.

Let’s briefly check the hedge fund interest towards ALNY stock. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp added position in the company after it grew 8% or 20,712 shares of its common stock. The hedge fund now owns 22,369 shares worth $1,942,300, SEC documents show. Toronto Dominion Bank cut assets in the stock as 16377.1 shares have been sold, reducing its stake by -10.9% to 14,592 shares which are currently valued at $1,267,023. In addition, Treasurer of the State of North Carolina recently reported that it now owns 64,910 shares making a total of $5,636,135 based on the recent price. This refelects a change of -1% in their ownership.